FIELD: chemistry.
SUBSTANCE: invention relates to the field of organic chemistry, namely to a compound of formula (I), or its tautomer, or a pharmaceutically acceptable salt, where each of Z1 and Z2: N and CR, where at least, one of Z1 and Z2 represents CR, and each R: H, C1-C4 alkyl and -N(R3)(R3); W: -O-, -N(C1-C4) alkyl and -C(R6)(R6) -, and each R6: H and C1-C4 alkyl, or two R6, bound with the same carbon atom, are taken together with the formation of =O, R1: a phenyl and heterocycle, which represents a saturated or unsaturated 5-6-member monocyclic ring, containing 1-3 heteroatoms, selected from atoms N, S and O, or a 8-12-member bicyclic ring, each cycle of which is selected from a saturated, unsaturated and aromatic cycle, containing 1-2 nitrogen atoms, where R1 is optionally substituted with one or more substituents, independently selected from halogen, C1-C4 alkyl, =O, fluorosubstituted C1-C2 alkyl, -O-R3, -(C1-C4 alkyl)-N(R3)(R3), -N(R3)(R3) and -C(O)-N(R3)(R3), R2: a phenyl and heterocycle, which represents an unsaturated 5-6-member monocyclic ring, containing 1-2 heteroatoms, selected from atoms N and O, or represents dihydrobenzofuranyl, where R2 is optionally substituted with 1-2 substituents, independently selected from a halogen, -C≡N, C1-C4 alkyl, C1-C2 fluorosubstituted alkyl, -O-R3, -(C1-C4 alkyl)-N(R3)(R3) and -N(R3)(R3); each R3: -C1-C4 alkyl; or two R3 are taken together with a nitrogen atom, which they are bound with, with the formation of a 4-8-member unsaturated heterocycle, optionally containing one additional heteroatom, selected from N and O, where in case when R3 represents an alkyl, the said alkyl is optionally substituted with two -OH groups, and when two R3 are taken together with a nitrogen atom, which they are bound with, with the formation of a 4-8-member saturated heterocycle, the said saturated heterocycle is optionally substituted with fluorine by any carbon atom; and is substituted with hydrogen by any capable of substitution nitrogen atom; p equals 1, 2 or 3; X2 is selected from -C(=O)-♣, -C(=O)-O-♣, -C(=O)-NH-♣, -S(=O)2-NH-♣ and -C(=O)-NH-CR4R5-♣, where: ♣ represents a site, by which X2 is bound with R1; and each R4 and R5 represents hydrogen. The invention also relates to compounds of formulas (IV), (V), (VI), particular the compounds, a pharmaceutical composition based on the compound of formulas (I), (IV)-(VI) and to a method of treatment, based on the application of the said compounds.
EFFECT: novel heterocyclic compounds, possessing sirtuin-modelling activity are obtained.
26 cl, 2 tbl, 40 ex
Title | Year | Author | Number |
---|---|---|---|
QUINAZOLINONE, QUINOLONE AND RELATED ANALOGUES AS SIRTUIN MODULATORS | 2009 |
|
RU2519779C2 |
CHROMENONE ANALOGUES AS SIRTUIN MODULATORS | 2009 |
|
RU2527269C2 |
OXAZINMONOACYLGLYCERIN LIPASE (MAGL) INHIBITORS | 2019 |
|
RU2794334C2 |
NOVEL CONDENSED PYRIDINE DERIVATIVES USED AS C-MET TYROSINE KINASE INHIBITORS | 2013 |
|
RU2619130C2 |
MKK4 PROTEIN KINASE INHIBITORS FOR STIMULATION OF LIVER REGENERATION OR REDUCTION OR PREVENTION OF HEPATOCYTE DEATH | 2019 |
|
RU2788000C2 |
NOVEL HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | 2019 |
|
RU2769507C1 |
HETEROCYCLIC COMPOUNDS, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2015 |
|
RU2667498C2 |
CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND USE THEREOF IN TREATING PSYCHOTIC DISORDERS | 2011 |
|
RU2586974C2 |
CARBOXAMIDE COMPOUNDS AND USING THEM AS CALPAIN INHIBITORS | 2010 |
|
RU2540856C2 |
HETEROCYCLIC COMPOUNDS | 2019 |
|
RU2809257C2 |
Authors
Dates
2015-05-20—Published
2010-10-29—Filed